MOTS-c

MOTS-c is one of the most hyped “exercise in a vial” peptides, and the biology behind it is genuinely interesting. But as of mid-2026, there’s essentially no human evidence that it actually does anything useful.

What it is

MOTS-c (short for “mitochondrial open reading frame of the 12S rRNA-c”) is a tiny peptide made of just 16 amino acids (the building blocks of proteins). What makes it unusual is where its instructions come from: not your main DNA in the cell’s nucleus, but a short stretch of code tucked inside the mitochondria — the little “power plants” that make energy inside your cells. It was discovered in 2015 by Changhan Lee, Pinchas Cohen, and colleagues at USC, and reported in the journal Cell Metabolism. In lab dishes and animals, MOTS-c switches on AMPK — a key enzyme that acts like a cellular fuel gauge, sensing when energy is low — and it can travel into the cell’s nucleus to change which genes are turned on when the body is under metabolic stress. It’s often lumped together with other peptides that come from the mitochondria, such as humanin.

The claims

Marketing pages and clinic websites sell MOTS-c as an “exercise mimetic” — basically a shortcut that’s supposed to copy the benefits of working out. The pitch is that it improves insulin sensitivity (how well your body responds to the hormone that manages blood sugar), boosts fat burning, reverses age-related metabolic decline, increases endurance, and helps you live longer. The story goes like this: your muscles release MOTS-c when you exercise, levels drop as you age, and topping it back up recreates the perks of training without the training.

What the evidence actually shows

The animal data are real and reasonably solid. In mice, MOTS-c improves insulin sensitivity, protects against weight gain from a fatty diet, nudges the body toward burning fat for fuel, and copies several of the changes you’d normally get from aerobic exercise. The human research, though, is almost all observational — meaning scientists simply measure and watch, rather than testing the peptide as a treatment. These studies note that MOTS-c levels in the blood sometimes track with a person’s age or metabolic health. But that doesn’t tell us anything about whether injecting it would actually help someone.

The missing piece is a real human treatment trial. The closest anyone got was CohBar, which tested CB4211 — a tweaked, lab-engineered version of MOTS-c, not MOTS-c itself — in an early-stage (Phase 1a/1b) study in people. The company shared early top-line results saying the compound seemed well tolerated, with some shifts in liver enzymes and blood sugar. But it later shut the program down after deciding the formula wasn’t good enough to keep developing, and CohBar was folded into another company (TuHURA Biosciences) in late 2023. No peer-reviewed human trial of MOTS-c itself has ever shown that it improves insulin sensitivity, body composition, or any real-world health outcome. One stubborn practical problem is getting the peptide to work in the body at all: these molecules are unstable, are poorly absorbed, and break down very quickly. The short version: an intriguing mechanism, strong rodent data, and no proven benefit in people.

Legal and regulatory status

MOTS-c is not approved by the FDA (or any equivalent regulator) for any use. It is not a dietary supplement. Anything sold online is unapproved and unregulated, with no guarantee that it’s the right substance, that it’s pure, or that the dose is what the label says.

It’s also banned in sport. The World Anti-Doping Agency (WADA) lists MOTS-c by name as a prohibited substance under Section S4.4 (Metabolic Modulators), subsection 4.4.1, Activators of AMP-activated protein kinase (AMPK) — banned at all times, both in and out of competition. According to USADA, there’s no way to get a medical exemption for it, because there’s no approved medical use to justify one.

Safety

There’s no completed, published clinical trial of MOTS-c itself, so the honest answer is that we don’t know how safe it is in humans — including whether there are any long-term risks. Reports from people experimenting on themselves (which is not the same as careful, controlled data) include a fast or irregular heartbeat, irritation at the injection site, trouble sleeping, and fever. And because the supply is unregulated, contamination and mislabeling are real added risks on top of any risk from the molecule itself.

Bottom line

MOTS-c rests on strong science in animals and almost nothing in humans. It may turn out to be useful for metabolic disease down the road, but for now it’s an experimental, unapproved, WADA-banned compound with no proven benefit in people and no established safety record. Anyone treating it as a proven metabolic or longevity therapy is way out ahead of the evidence. None of this is medical advice.

Evidence grade: 3/10 · Animal only.

Sources

• Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 2015 (PMID: 25738459)
• MOTS-c: a promising mitochondrial-derived peptide for therapeutic exploitation (review, Frontiers in Endocrinology, 2023; PMC9905433)
• Kim KH, et al. The mitochondrial-derived peptide MOTS-c is a regulator of plasma metabolites and enhances insulin sensitivity (rodent study, Physiological Reports, 2019; PMC6640593)
• What is the MOTS-c peptide? — USADA
• WADA Prohibited List — World Anti-Doping Agency